Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 13/20 | 0.45 |
| ▸ | AXL | P30530 | 10/20 | 0.45 |
| ▸ | KDR | P35968 | 9/20 | 0.45 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.45 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.45 |
| ▸ | RIPK3 | Q9Y572 | 2/20 | 0.45 |
| ▸ | MST1R | Q04912 | 2/20 | 0.45 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.45 |
| ▸ | ABL1 | P00519 | 1/20 | 0.45 |
| ▸ | LCK | P06239 | 1/20 | 0.45 |
| ▸ | LYN | P07948 | 1/20 | 0.45 |
| ▸ | RET | P07949 | 1/20 | 0.45 |
| ▸ | HCK | P08631 | 1/20 | 0.45 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.45 |
| ▸ | BCR | P11274 | 1/20 | 0.45 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.45 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.45 |
| ▸ | FLT3 | P36888 | 1/20 | 0.45 |
| ▸ | ABL2 | P42684 | 1/20 | 0.45 |
| ▸ | FRK | P42685 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3549472 | 0.93 | MET (0.45) | METAXLKDRNTRK1RIPK2 | |
| SCHEMBL3553757 | 0.93 | MET (0.42) | METAXLKDRNTRK1RIPK2 | |
| SCHEMBL3612262 | 0.92 | MET (0.46) | METAXLKDRNTRK1RIPK2 | |
| SCHEMBL3560132 | 0.92 | MET (0.49) | METAXLKDRNTRK1RIPK2 | |
| SCHEMBL3552175 | 0.90 | AXL (0.48) | METAXLKDRNTRK1RIPK2 | |
| SCHEMBL3555605 | 0.90 | MET (0.47) | METAXLKDRNTRK1RIPK2 | |
| SCHEMBL3558555 | 0.90 | MET (0.45) | METAXLKDRNTRK1RIPK2 | |
| SCHEMBL3555866 | 0.90 | KDR (0.46) | METAXLKDRNTRK1RIPK2 | |
| SCHEMBL3553891 | 0.89 | MET (0.52) | METAXLKDRNTRK1RIPK2 | |
| SCHEMBL3558584 | 0.89 | MET (0.52) | METAXLKDRNTRK1RIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288538-B2 | Pyridine derivatives and pyrimidine derivatives (3) | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-10-16 | — | — | US | disclosed |
| US-7855290-B2 | N-[4-({2-[({4-[2-(Dimethylamino)ethyl]piperazin-1-yl}carbonyl)amino]pyridin-4-yl}oxy)-2-fluorophenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide; hepatocyte growth factor receptor (HGFR) inhibitors; antitumor, -carcinogenic, -metastasis agents | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-12-21 | — | — | US | disclosed |
| US-20100075944-A1 | NOVEL PYRIDINE DERIVATIVES AND PYRIMIDINE DERIVATIVES (3) | MATSUSHIMA TOMOHIRO | 2010-03-25 | — | — | US | disclosed |
| US-20080319188-A1 | Novel pyridine derivatives and pyrimidine derivatives (3) | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080319188-A1 | Novel pyridine derivatives and pyrimidine derivatives (3) | HGF, MET, FLT4 | MET 2/4885AXL 88/4885KDR 8/4885 |
| US-20100075944-A1 | NOVEL PYRIDINE DERIVATIVES AND PYRIMIDINE DERIVATIVES (3) | HGF, MET, HDGF | MET 2/4885AXL 100/4885KDR 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.